The 200 SMA at $104.69 is rolling over, not rising, and will flip from support to resistance on a close below this level ($1.60 below current price)

• 200 SMA at $104.69 — your so-called "gravity well" — is rolling over, not rising
• A close below $104.69 — which is $1.60 below where we are today — flips that gravity well into resistance

↩ rebuts: “Bull's claim that the 200 SMA is a "gravity well" providing support”

MACD has crossed bearish and is accelerating lower, not showing exhaustion — histogram at -1.56 is deepening, not bottoming

• MACD at -0.88 from +4.34 is a 5.2-point slide, not an "exhaustion"
• MACD that flipped negative on September 10 and has been accelerating lower every session since
• Histogram at -1.56 is deepening, not bottoming

↩ rebuts: “Bull's claim that MACD crossing into negative territory signals "exhaustion" and a potential reversal”

RSI remains in a confirmed downtrend — a reversal requires RSI to curl back above 50 and print higher highs, neither of which has happened

• RSI is still trending lower on the daily
• From 77.97 (August 24) to 37.60 today, with one dead-cat bounce along the way
• A confirmed reversal requires RSI to curl back above 50 and print higher highs — neither of which has happened

↩ rebuts: “Bull's claim that the RSI bounce from 33.67 to 37.60 signals a reversal”

ABT faces a four-resistance gauntlet to reach the $110–$116 target: VWMA at $108.94, 10 EMA at 106.14, 50 SMA at 105.36, and Bollinger middle at 110.26

• To get there, price has to break through the 10 EMA at 106.14
• 50 SMA at 105.36
• Bollinger middle at 110.26
• VWMA at 108.94
• every single one of these levels is currently above price and acting as resistance

↩ rebuts: “Bull's claim of "asymmetric upside" to $110–$116”

Forward P/E of 16.99x vs TTM 33.36x gap requires ~96% earnings recovery in less than a year — a multi-variable bet where the bear case only needs one variable to fail

• Market is pricing in $6.07 of forward EPS
• Current TTM EPS of $3.09
• Need ~96% earnings recovery in less than a year
• Zero acquisition integration friction
• Flawless synergy realization on a $19.8B deal
• Stable SG&A (after the 18% sequential spike)
• A macro environment that doesn't compress med-device multiples

↩ rebuts: “Bull's use of forward P/E as evidence of undervaluation”

Q2 2026 showed severe fundamental deterioration: EPS collapsed 47% YoY, operating margin compressed to 14.71% vs 17% historical average, net margin at 11.65% vs 14-16% historical

• EPS collapsed to $0.53 from $1.01 a year prior — that's a 47% YoY decline
• Operating margin compressed to 14.71% vs the 5-year historical average of ~17%
• That's 230 basis points of structural margin loss on a $46B+ revenue base
• Net margin at 11.65% is well below the historical ~14–16% range

↩ rebuts: “Bull's characterization of Q2 weakness as "transitory integration costs"”

SG&A spiked $610M sequentially and net debt nearly tripled to $27.24B, creating leverage risk and dividend sustainability questions

• SG&A spiked to $3.74B from $3.13B — a $610M sequential jump in a single line item
• Net debt nearly tripled from $4.41B to $27.24B in one quarter
• D/E at 63% vs historical ~25–30%
• Net Debt/EBITDA at ~2.33x today — if synergies don't materialize on schedule, this climbs past 2.5x and approaches the 3.0x zone

↩ rebuts: “Bull's framing of the dividend raise as a "confidence signal"”

The $19.8B acquisition is goodwill and intangibles that need to be earned back, with undisclosed synergies and integration risk not yet validated

• $11.18B increase in goodwill and $12.34B increase in intangibles
• What was acquired?
• What are the projected synergies?
• What's the integration timeline?
• What happens to EPS if synergies are 50% of plan?

↩ rebuts: “Bull's framing of the acquisition as an "inorganic growth lever"”

The 10Y Treasury at 5%+ makes ABT's 2.47% yield uncompelling vs money-market funds yielding 4.5-5% with zero credit or equity risk

• With the 10Y Treasury at 5%+, the relative attractiveness of ABT's 2.47% yield has shrunk dramatically
• A money-market fund yields ~4.5–5% with zero credit risk, zero integration risk, and zero equity-market drawdown risk
• The income-investor argument for ABT has been materially weakened by the rate regime

↩ rebuts: “Bull's claim that the higher-for-longer rate regime is a "tailwind" for healthcare defensives”

ABT is 25% below its 52-week high of $137.49 in a "rising rates favor defensives" regime — if the bull thesis were true, ABT should be near its high, not 25% off

• ABT is 25% below its 52-week high of $137.49
• In a "rising rates favor defensives" regime

↩ rebuts: “Bull's macro tailwind argument”

The bear case requires only one of three plausible outcomes to take ABT to $98–100: 200 SMA giving way, lower Bollinger Band at $101.09 breaking, or Q3 confirming Q2 margin compression was structural

• 200 SMA to give way (highly probable — it's rolling over)
• OR the lower Bollinger Band at $101.09 to break (a $2 move)
• OR Q3 earnings to confirm that Q2 margin compression was structural, not transitory
• A confirmed break of the lower band opens the path to $92–95
• From $103.09, that's 8–10% of additional downside before meaningful support

↩ rebuts: “Bull's claim of asymmetric upside with ~3% downside vs ~13% upside”

Competitors are not standing still: Boston Scientific is wounded not dead, JNJ has larger R&D budget, Medtronic raised its 2027 outlook, and Dexcom's G7 is closing the CGM accuracy/form factor gap

• Boston Scientific is wounded, not dead. A 58% drawdown off a 52-week high often sets up value-driven acquisitions or operational turnarounds
• Johnson & Johnson (JNJ) is in EP too, with the CARTO and Biosense Webster franchise. JNJ has a vastly larger R&D budget than ABT
• Medtronic (MDT) just raised its 2027 outlook
• Dexcom's G7 is closing the gap on accuracy and form factor

↩ rebuts: “Bull's claim of competitive moat protection”